(Q38848537)

7 September 2017

1 reference

title

Advanced Hepatocellular Cancer: the Current State of Future Research (English)

1 reference

7 September 2017

main subject

hepatocellular carcinoma

1 reference

Louise C Connell

1

1 reference

7 September 2017

James J Harding

series ordinal

2

1 reference

7 September 2017

Ghassan K Abou-Alfa

series ordinal

3

1 reference

7 September 2017

publication date

1 August 2016

1 reference

Current Treatment Options in Oncology

7 September 2017

published in

1 reference

7 September 2017

volume

17

1 reference

7 September 2017

issue

8

1 reference

7 September 2017

page(s)

43

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-016-0415-3

7 September 2017

exact match

0 references

cites work

Liver-directed therapies for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Targeting the HGF/c-MET pathway in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Selection of patients with hepatocellular carcinoma for sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Immune response regulation in the tumor microenvironment by hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepato-cellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0415-3

c-met mRNA overexpression in human hepatocellular carcinoma

21 January 2018

1 reference

12 December 2020

Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway

1 reference

12 December 2020

In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells.

1 reference

12 December 2020

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

1 reference

12 December 2020

Hepatocellular carcinoma in Italy: report of a clinical trial with intravenous doxorubicin

1 reference

12 December 2020

TACE and sorafenib: a good marriage?

1 reference

12 December 2020

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

1 reference

12 December 2020

The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy

1 reference

12 December 2020

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo

1 reference

12 December 2020

Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma

1 reference

12 December 2020

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

1 reference

12 December 2020

Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma

1 reference

12 December 2020

Expression of the c-met protooncogene in human hepatocellular carcinoma

1 reference

12 December 2020

Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas

1 reference

12 December 2020

Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization

1 reference

12 December 2020

An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

1 reference

12 December 2020

10.1007/S11864-016-0415-3

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1013085769

0 references

1 reference